ExcelMale
Menu
Home
What's new
Latest activity
Forums
New posts
Search forums
What's new
New posts
Latest activity
Videos
Lab Tests
Doctor Finder
Buy Books
About Us
Men’s Health Coaching
Log in
Register
What's new
Search
Search
Search titles only
By:
New posts
Search forums
Menu
Log in
Register
Navigation
Install the app
Install
More options
Contact us
Close Menu
Forums
Testosterone Replacement, Low T, HCG, & Beyond
When Testosterone Is Not Enough
ED Drugs Not Tied to Prostate Cancer Return
JavaScript is disabled. For a better experience, please enable JavaScript in your browser before proceeding.
You are using an out of date browser. It may not display this or other websites correctly.
You should upgrade or use an
alternative browser
.
Reply to thread
Message
<blockquote data-quote="Nelson Vergel" data-source="post: 32277" data-attributes="member: 3"><p>One year ago, German researchers published a <a href="http://www.medscape.com/viewarticle/838783" target="_blank">single-center study</a> of 4752 men with prostate cancer that showed an association between the use of erectile dysfunction (ED) drugs (after radical prostatectomy) and biochemical recurrence.</p><p></p><p>"The study made quite a splash," said Stacy Loeb, MD, a urologist at New York University in New York City, who was not involved with the German research.</p><p>Some clinicians had a subsequent "hesitation" to use these drugs because of "concern that the finding was real," she told <em>Medscape Medical News</em>.</p><p></p><p>The drugs, known as phosphodiesterase type 5 inhibitors (PDE5i), are a first-line treatment for the ED that commonly occurs after prostatectomy.</p><p></p><p>Last year, the German researchers said they were "astonished" by the link between the use of a PDE5i and biochemical recurrence after prostatectomy. They had theorized that the ED drugs would be protective.</p><p></p><p>In their new study, Dr Loeb and a team of international researchers decided to take another look at the issue.</p><p></p><p>But they used bigger, more authoritative data sources from Sweden: the nationwide population-based National Prostate Cancer Register, and the Prescribed Drug Register.</p><p>Of the men with localized prostate cancer who underwent primary radical prostatectomy or radiation therapy in 2006 or 2007 and who had 5 years of follow-up, the investigators identified 293 who had a biochemical recurrence after treatment and 5767 control subjects who did not.</p><p></p><p>PDE5i pills were used after treatment by 150 (51%) men in the recurrence group and 3334 (58%) in the control group. The pills used included sildenafil (<em>Viagra</em>), vardenafil (<em>Levitra</em>), and tadalafil (<em>Cialis</em>).</p><p></p><p>"We found no significant relationship between PDE5i use with prostate cancer recurrence after treatment," Dr Loeb and her colleagues conclude in their study, which was <a href="http://www.europeanurology.com/article/S0302-2838(15)01221-X/abstract/phosphodiesterase-type-5-inhibitor-use-and-disease-recurrence-after-prostate-cancer-treatment" target="_blank">published online</a> December 30, 2015 in <em>European Urology</em>.</p><p></p><p><a href="http://www.medscape.com/viewarticle/858183?src=wnl_edit_tpal" target="_blank">http://www.medscape.com/viewarticle/858183?src=wnl_edit_tpal</a></p></blockquote><p></p>
[QUOTE="Nelson Vergel, post: 32277, member: 3"] One year ago, German researchers published a [URL="http://www.medscape.com/viewarticle/838783"]single-center study[/URL] of 4752 men with prostate cancer that showed an association between the use of erectile dysfunction (ED) drugs (after radical prostatectomy) and biochemical recurrence. "The study made quite a splash," said Stacy Loeb, MD, a urologist at New York University in New York City, who was not involved with the German research. Some clinicians had a subsequent "hesitation" to use these drugs because of "concern that the finding was real," she told [I]Medscape Medical News[/I]. The drugs, known as phosphodiesterase type 5 inhibitors (PDE5i), are a first-line treatment for the ED that commonly occurs after prostatectomy. Last year, the German researchers said they were "astonished" by the link between the use of a PDE5i and biochemical recurrence after prostatectomy. They had theorized that the ED drugs would be protective. In their new study, Dr Loeb and a team of international researchers decided to take another look at the issue. But they used bigger, more authoritative data sources from Sweden: the nationwide population-based National Prostate Cancer Register, and the Prescribed Drug Register. Of the men with localized prostate cancer who underwent primary radical prostatectomy or radiation therapy in 2006 or 2007 and who had 5 years of follow-up, the investigators identified 293 who had a biochemical recurrence after treatment and 5767 control subjects who did not. PDE5i pills were used after treatment by 150 (51%) men in the recurrence group and 3334 (58%) in the control group. The pills used included sildenafil ([I]Viagra[/I]), vardenafil ([I]Levitra[/I]), and tadalafil ([I]Cialis[/I]). "We found no significant relationship between PDE5i use with prostate cancer recurrence after treatment," Dr Loeb and her colleagues conclude in their study, which was [URL="http://www.europeanurology.com/article/S0302-2838(15)01221-X/abstract/phosphodiesterase-type-5-inhibitor-use-and-disease-recurrence-after-prostate-cancer-treatment"]published online[/URL] December 30, 2015 in [I]European Urology[/I]. [URL]http://www.medscape.com/viewarticle/858183?src=wnl_edit_tpal[/URL] [/QUOTE]
Insert quotes…
Verification
Post reply
Share this page
Facebook
Twitter
Reddit
Pinterest
Tumblr
WhatsApp
Email
Share
Link
Sponsors
Forums
Testosterone Replacement, Low T, HCG, & Beyond
When Testosterone Is Not Enough
ED Drugs Not Tied to Prostate Cancer Return
This site uses cookies to help personalise content, tailor your experience and to keep you logged in if you register.
By continuing to use this site, you are consenting to our use of cookies.
Accept
Learn more…
Top